Fig. 4: Progression free survival in biomarker subgroups. | Nature Communications

Fig. 4: Progression free survival in biomarker subgroups.

From: Olaparib, durvalumab, and cyclophosphamide, and a prognostic blood signature in platinum-sensitive ovarian cancer: the randomized phase 2 SOLACE2 trial

Fig. 4: Progression free survival in biomarker subgroups.

Kaplan-Meier plots of progression-free survival according to (A) homologous recombination deficiency status, (B) CUP-CC status, and (C) combined statuses of homologous recombination deficiency and CUP-CC Arm A, olaparib followed by olaparib-durvalumab; Arm B, olaparib-LDCy followed by olaparib-durvalumab; Arm C olaparib monotherapy, PFS progression-free survival, CI confidence interval, HRD homologous recombination deficient, HRP homologous recombination proficient, HR* hazard ratio, CCUP-CC, CCR4 up-regulation, cytokines, and chemokines. PFS was estimated using Kaplan-Meier methodology, and a two-sided 95% CI for 36-week PFS rate was calculated with the log-log transformation method. The HR and corresponding two-sided 95% CI were estimated using a Cox proportional hazards model, stratified by treatment arms. Source data are provided as a Source Data file.

Back to article page